London UK – 01 March 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the closure of an agreement with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.
GSK has divested its anaesthesia portfolio to Aspen (excluding the US and Canada which had been previously divested) for £180m plus milestones of up to £100m.
- GSK’s anaesthesia portfolio consists of Ultiva, Nimbex, Tracrium, Mivacron and Anectine.
- GSK 2016 full year sales of the anaesthesia portfolio were approximately £70 million.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com/about-us.